<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433992</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AI065348-01A2</org_study_id>
    <nct_id>NCT00433992</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications</brief_title>
  <official_title>Effects of Thymidine Sparing Regimens on Mitochondrial Metabolism and Adipocyte Apoptosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the effects of certain anti-HIV medications on
      mitochondrial activity and fat cell death. This study will enroll participants from another
      study, ACTG A5202, who are on treatment regimens that do not include zidovudine, stavudine,
      or other thymidine-containing anti-HIV medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to observe the effects of anti-HIV medication lacking
      thymidine on mitochondrial metabolism and adipocyte apoptosis (fat cell death). Changes in
      mitochondrial metabolism and increases in adipocyte apoptosis are associated with
      lipoatrophy. Lipoatrophy is a common condition characterized by loss of subcutaneous fat and
      can be caused by many anti-HIV medications. This study will examine the metabolic
      consequences of the use of thymidine analogue-sparing treatment regimens.

      This study will evaluate HIV infected patients who are enrolled in ACTG A5202, starting their
      first nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen. This regimen will
      include either tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or abacavir/lamivudine
      (ABC/3TC), which are thymidine-sparing regimens. The changes in mitochondrial activity and
      fat cell death will be compared between participants taking thymidine-sparing regimens
      (TDF/FTC or ABC/3TC) and thymidine-containing regimens.

      This study will last for 96 weeks, with two study visits occurring at entry and another visit
      at Week 96. During each visit, a dual energy x-ray absorptiometry (DEXA) scan and blood
      collection will occur, and a fat biopsy will be performed in the lower abdomen under local
      anesthetic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mitochondrial Activity</measure>
    <time_frame>Entry, Week 96</time_frame>
    <description>mtDNA content in adipose tissue was measured by quantitative real-time polymerase chain-reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fat Apoptosis</measure>
    <time_frame>Entry, Week 48</time_frame>
    <description>Changes in limb fat from 0 to 48 weeks measured with whole-body dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>ABC/3TC</arm_group_label>
    <description>HIV-infected subjects were given Abacavir-Lamuvidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF/FTC</arm_group_label>
    <description>HIV-infected patients were given tenofovir DF-emtricitabine</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients who are enrolled in ACTG A5202, starting their first nucleoside
        reverse transcriptase inhibitor (NRTI)-containing regimen
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected

          -  Enrolling in ACTG A5202 and its metabolic substudy ACTG A5224

        Exclusion Criteria:

          -  Bleeding problems

          -  Cannot undergo fat biopsies

          -  Require aspirin anytime in the 7-day period prior to each biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace McComsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct/show/NCT00118898</url>
    <description>Click here for more information on ACTG A5202 and ACTG 5224</description>
  </link>
  <link>
    <url>https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/22/61/hiv-and-lipodystrophy</url>
    <description>Click here for more information on lipodystrophy</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <results_first_submitted>March 28, 2017</results_first_submitted>
  <results_first_submitted_qc>June 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</investigator_affiliation>
    <investigator_full_name>Grace McComsey</investigator_full_name>
    <investigator_title>Grace McComsey, MD, Case School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Mitochondria</keyword>
  <keyword>Fat apoptosis</keyword>
  <keyword>Lipoatrophy</keyword>
  <keyword>Lipodystrophy</keyword>
  <keyword>Thymidine</keyword>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABC/3TC</title>
          <description>HIV-infected subjects taking abacavir-lamivudine (ABC/3TC)</description>
        </group>
        <group group_id="P2">
          <title>TDF/FTC</title>
          <description>HIV-infected subjects taking tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-lamivudine (ATV-r)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABC/3TC</title>
          <description>HIV-infected subjects taking abacavir-lamivudine (ABC/3TC)</description>
        </group>
        <group group_id="B2">
          <title>TDF/FTC</title>
          <description>HIV-infected subjects taking tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-lamivudine (ATV-r)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mitochondrial Activity</title>
        <description>mtDNA content in adipose tissue was measured by quantitative real-time polymerase chain-reaction.</description>
        <time_frame>Entry, Week 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC+EFV</title>
            <description>HIV-infected subjects taking abacavir-lamivudine (ABC/3TC) with Efavirenz at baseline</description>
          </group>
          <group group_id="O2">
            <title>TDF/FTC+EFV</title>
            <description>HIV-infected subjects taking tenofovir DF-emtricitabine (TDF/FTC) with Efavirenz at baseline</description>
          </group>
          <group group_id="O3">
            <title>ATV/r +TDF/FTC</title>
            <description>HIV infected subjects taking atazanavir-ritonavir with tenofovir DF-emtricitabine at baseline</description>
          </group>
          <group group_id="O4">
            <title>ATV/r +ABC/3TC</title>
            <description>HIV-infected subjects taking atazanavir-ritonavir with abacavir-lamivudine at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mitochondrial Activity</title>
          <description>mtDNA content in adipose tissue was measured by quantitative real-time polymerase chain-reaction.</description>
          <units>copies/cell</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1250" lower_limit="998" upper_limit="1886"/>
                    <measurement group_id="O2" value="1312" lower_limit="920" upper_limit="1609"/>
                    <measurement group_id="O3" value="1150" lower_limit="721" upper_limit="1423"/>
                    <measurement group_id="O4" value="1125" lower_limit="1049" upper_limit="1588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fat Apoptosis</title>
        <description>Changes in limb fat from 0 to 48 weeks measured with whole-body dual-energy x-ray absorptiometry</description>
        <time_frame>Entry, Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABC/3TC</title>
            <description>HIV-infected subjects taking abacavir-lamivudine (ABC/3TC)</description>
          </group>
          <group group_id="O2">
            <title>TDF/FTC</title>
            <description>HIV-infected subjects taking tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-lamivudine (ATV-r)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat Apoptosis</title>
          <description>Changes in limb fat from 0 to 48 weeks measured with whole-body dual-energy x-ray absorptiometry</description>
          <units>g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="906" lower_limit="-349" upper_limit="1900"/>
                    <measurement group_id="O2" value="1479" lower_limit="353" upper_limit="3032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>the adverse event data was collected over the duration of the study of 96 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ABC/3TC</title>
          <description>HIV-infected subjects taking abacavir-lamivudine (ABC/3TC)</description>
        </group>
        <group group_id="E2">
          <title>TDF/FTC</title>
          <description>HIV-infected subjects taking tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-lamivudine (ATV-r)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations included small sample size and premature study discontinuation before week 96</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Grace McComsey</name_or_title>
      <organization>Case Western Reserve University</organization>
      <phone>216-844-2739</phone>
      <email>mccomsey.grace@clevelandactu.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

